Abstract
Deregulation of the cell cycle is one of the first events during malignant transformations that convert normal cells into tumor cells. Cyclin-dependent kinases (CDKs) are key elements of the mammalian genome surveillance machinery that controls the cell cycle. Their activity (which is normally regulated via cyclin binding, phosphorylation events and interactions with endogenous inhibitors of CDKs, CKIs) is frequently altered in human cancers. Therefore, strenuous efforts are being made to develop means to counter cell cycle malfunctions using pharmacological inhibitors of CDKs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
